Kornimate/medical-research-clean huggingface dataset:
expressive writing for co-occurring depression and alcohol misuse

Conditions: Depression; Alcohol, Drinking

Summary: \*\*\*please note that this study does not offer comprehensive treatment program for alcohol abuse or depression. please do not contact the study staff if you are seeking psychological treatment. further, this study is only enrolling people who are clients at career and recovery resources, inc., in houston. the hypothesis is that writing about feelings and thoughts will help people who are in group treatment feel less depressed and abuse alcohol less.

expressive writing applied to a variety of populations (e.g., hiv, cancer, ptsd, depression) has been associated with health improvements, reductions in symptoms of emotional distress, and one preliminary study found reductions in alcohol misuse among college students. data suggest that expressive writing is a technique to facilitate emotional processing that can influence a number of clinical outcomes by facilitating cognitive restructuring (hunt, 1998; pennebaker, 2004). in addition to examining cognitive content change following expressive writing, we believe the effects of emotional writing on mood and drinking may involve two additional processes that have been found significant for both depression and alcohol misuse, namely experiential avoidance and ruminative thinking. we hypothesize that expressive writing will lead to less drinking and enhanced mood by reducing: (1) negative thought content, (2) experiential avoidance of unpleasant private events (e.g., negative thoughts, feelings, bodily sensations), and (3) ruminative thinking.

Eligibility criteria:
\*\*\*please note that this study does not offer comprehensive treatment program for alcohol abuse or depression. please do not contact the study staff if you are seeking psychological treatment. further, this study is only enrolling people who are clients at career and recovery resources, inc., in houston. inclusion criteria: * enrolled in group therapy program at career and recovery resources, inc. * must be at least 18. * willing and able to participate in the study through the one month follow up. * able to provide the contact information of at least two people who can generally locate their whereabouts. * speak english fluently. exclusion criteria: * inability to read, write, speak english. * history of bipolar or psychotic disorders. * severe medical, cognitive and /or psychiatric impairment that precludes cooperation with study protocol. * substance withdrawal symptoms requiring medical attention. * currently receiving other individual psychosocial therapy outside of c\&r for substance abuse or other psychiatric conditions with the exception of aa, na or ca. * impending incarceration or other factor that would create inability or unwillingness to participate in the 6 week long study period (e.g., halfway house or other aftercare program restrictions).

Keywords: expressive writing ruminating ruminative thinking experiential avoidance depression alcohol drinking emotional processing
short-term perfusion angiography pilot study (spa)

Conditions: Peripheral Arterial Disease

Summary: the short term perfusion angiography (spa) study is designed to collect 2d perfusion data from critical limb ischemia (cli) endovascular (interventional) procedures for information on device performance in a real-world setting.

this clinical study is designed to collect pre and post procedural imaging data using 2d perfusion (2dp) software in patients receiving an endovascular intervention.

Eligibility criteria:
inclusion criteria: 1. subject is ≥ 18 years of age. 2. subject or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent 3. subject has appropriate femoral arterial access 4. subject presents with a rutherford classification of 4 to 6. 5. planned dsa with endovascular intervention below the knee on one or both limbs. this may include patients who undergo: 1. above the knee (atk) and below the knee (btk) intervention during the same procedure. 2. only btk intervention. 3. atk intervention with staged future btk intervention within 6 weeks of the initial procedure. exclusion criteria: 1. subjects whose atk intervention is limited to only the common femoral or iliac arteries 2. subject is unwilling or unable to comply with the protocol including all follow-up visits 3. subject with active atrial fibrillation at time of procedure 4. critical limb ischemia due to acute arterial occlusion. 5. subject with documented ejection fraction \< 40% and/or prolonged bradycardia (\< 60 beats per minute) 6. inability to collect toe pressure on index limb from subject 7. subjects with history of or known reaction or sensitivity to contrast agent that cannot be pre-medicated or any other condition that precludes an endovascular intervention and dsa 8. female subject of childbearing potential who is pregnant (she must have negative pregnancy test within the 48 hours prior to enrollment), or plans a pregnancy during study period, 9. subject life expectancy \< 3 months, 10. subject is participating in a potentially confounding device or drug clinical trial that interferes with this study 11. investigator considers subject to be a poor candidate for the study or believes that the patient may compromise the study, e.g., concomitant conditions (reasons will be documented) )
wheeze detection using aevice medical device

Conditions: Subject Presenting Wheeze; COPD; Asthma

Summary: the primary objective of this study is to determine if aevice medical device can detect wheeze as accurately as a physician through auscultation. the secondary objective is to investigate if aevice medical device can be used for remote auscultation of the lung.


Eligibility criteria:
inclusion criteria: * the subject is willing and parents/guardians are able to give informed consent for participation in the study. * male or female, aged 3 -18 years. * presenting with wheeze. * able (in the investigators opinion) and willing to comply with all study requirements exclusion criteria: * any other significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the study, or may influence the result of the study, or the subject's ability to participate in the study.

Keywords: wheeze auscultation
the effect of remote ischemic preconditioning on major organ function in patients with coronary artery disease undergoing orthopedic surgery

Conditions: Angina Pectoris; Myocardial Infarction

Summary: the investigators attempt to investigate the organ protective effect of remote ischemic conditioning in patients undergoing non-cardiac surgery with history of ischemic heart disease.

when adult patients with ischemic heart disease undergo non-cardiac surgery, perioperative ischemic complication may occur. these morbidity results in poor clinical outcomes. the incidence of perioperative myocardial ischemic event has been reported to be up to 19.7%. remote ischemic preconditioning (ripc) is a concept that a brief ischemic reperfusion of upper or lower extremity can transfer protection to the other vital organs from sustained ischemic reperfusion injury. although ripc is extensively studied in high risk cardiovascular surgery, it has not been tested in a non-cardiac surgery patients with a history of ischemic heart disease. major organ injury including heart, lung and kidney will be evaluated in this randomized controlled trial.

Eligibility criteria:
inclusion criteria: * adults patients who undergo orthopedic surgery with duration of longer than one hour * patients with a history of ischemic heart disease (stable or unstable angina, myocardial infarction) * american society of anesthesiology (asa) physical status classification of 1, 2, or 3 exclusion criteria: * peripheral vascular disease involving upper or lower extremity * orthopedic surgery which uses the tourniquet

Keywords: remote ischemic conditioning orthopedic surgery ischemic heart disease
observational study to evaluate mechanisms of aromatase inhibitor associated musculoskeletal symptoms

Conditions: Breast Cancer; Arthralgia

Summary: early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease. typical agents used for treatment include tamoxifen and the aromatase inhibitors. in postmenopausal women, aromatase inhibitor therapy is increasingly common because it is associated with fewer long-term serious toxicities compared to tamoxifen. however, aromatase inhibitors cause arthralgias in 40-50% of patients, which can influence adherence to therapy and can lead to treatment discontinuation in a minority of cases. the mechanism underlying development of this toxicity remains unclear, and predictors of who will develop these symptoms remain undefined. this observational study is designed to collect patient-reported outcomes and serial serum samples in order to investigate potential etiologies of this bothersome toxicity.


Eligibility criteria:
inclusion criteria: * stage i-iii breast cancer who are scheduled to receive endocrine therapy with an aromatase inhibitor * all prior surgery, chemotherapy, and radiation therapy should be complete or should be completed by the time of ai treatment initiation (within 28 days of study enrollment) * age 21 and above and postmenopausal

Keywords: joint pain hormone receptor positive breast cancer estrogen androgen
to evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.

Conditions: Seizure Disorder, Partial

Summary: to evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.


Eligibility criteria:
inclusion criteria: * must have met the inclusion criteria for preceding double-blind study * have received double-blind study medication and wish to receive open-label pregabalin. exclusion criteria: * cannot have absence seizures
antagonist protocol in ivf

Conditions: Infertility

Summary: the antagonist protocol in a novel method of stimulation in the in vitro fertilization (ivf) patients. it has been tried in poor responders, polycystic ovary (pco) patients and normal females undergoing ivf. can it be used with the same efficacy in all patients?


Eligibility criteria:
inclusion criteria: * age: 20- 44 years * poor responder females according to bologna criteria * polycystic ovarian disease females according to rotterdam criteria * females with infertility causes other than poor responders, or pco; male factor or tubal block exclusion criteria: * refusal to get enrolled in the study * cases of infertility due to severe male factor

Keywords: infertility
to evaluate the efficacy and safety of tafamidis meglumine soft capsules in the treatment of adult patients with transthyretin amyloid polyneuropathy

Conditions: Transthyretin Amyloid Polyneuropathy

Summary: the purpose of this study is to evaluate the efficacy and safety of tafamidis meglumine soft capsules in the treatment of adult patients with transthyretin amyloid polyneuropathy


Eligibility criteria:
inclusion criteria: * male or female participants between the ages of 18 and 80 years. * participant has amyloid deposits confirmed by biopsy (biopsy must have been performed within 5 years prior to enrollment). * participant must have a ttr mutation that is associated with attr-pn (ttr mutation test must have been performed within 5 years prior to enrollment). * participant has peripheral neuropathy at screening. * participant has a karnofsky performance status score ≥50. * stages of disease according to symptom severity-stage 1. exclusion criteria: * participant has other causes of amyloidosis, such as light chain amyloidosis, aa amyloidosis. * participant has used tafamidis within 2 months prior to enrollment. * participant has used diflunisal, patisiran, inotersen, or other agents for familial amyloidosis within 30 days prior to enrollment or plan to use them during the study period. * participant has used non-protocol nsaids more than 4 times within 30 days prior to enrollment or plan to use them more than 4 times per month during the study period. * participant has used doxycycline,tauroursodeoxycholate within 14 days prior to enrollment or plan to use them during the study period. * participant has sensory motor neuropathy caused by other causes, such as chronic inflammatory demyelinating polyradiculopathy, chronic idiopathic axonal neuropathy, diabetic neuropathy, chronic alcoholic neuropathy, paraneoplastic neuropathy,guillain-barre syndrome, vitamin b12 deficiency. * participant has received liver or any other organ except cornea transplantation.
comparison of 2 doses of corticosteroid subacromial injections for the treatment of painful shoulder

Conditions: Tendonitis; Bursitis

Summary: the use of corticosteroid subacromial injections have been found to be effective for the treatment of shoulder pain. higher doses may be better than lower doses for subacromial corticosteroid injection for rotator cuff tendonitis. the investigators aim this study to compare 2 doses of corticosteroids.


Eligibility criteria:
inclusion criteria: * subacromial bursitis * tendinitis * calcific tendonitis exclusion criteria: * rotator cuff tear * osteoarthritis * pregnancy * local or systemic infection * steroid or lidocaine sensitivity

Keywords: shoulder subacromion corticosteroid bursitis tendinitis calcific tendonitis subacromial bursitis rotator cuff tendinitis
management of warthin tumor of parotid gland.

Conditions: Warthin's Tumor of Parotid Gland

Summary: comparison between ultrasound-guided ethanol sclerotherapy (uges) \& surgical excision in management of warthin tumor of parotid gland.

warthin tumor (also known as cystadenolymphoma), is a benign and frequent salivary gland neoplasm. it represents about 2% to 15% of all primary epithelial tumors of the parotid gland. warthin tumor is histologically characterized by a dense lymphoid stroma and a double layer of oncocytic epithelium with a papillary and cystic architectural pattern. its etiology: remains controversial. incidence: it is the second most frequent benign neoplasm of the salivary glands after pleomorphic adenoma. pathophysiology: initially, hildebrand proposed that the lesion may be remnants of the branchial pouches and a variant of the lateral cervical cyst. later, albrech and artz proposed the heterotropic origin of warthin tumor from the neoplastic proliferation of salivary gland ducts present within intra- or para-parotid nodes. histopathology: grossly, warthin tumor is a well-circumscribed spherical to oval mass. on cut section, there are solid areas and multiple cysts with papillary projections. cytology: smears characteristically show oncocytic epithelial cells without atypia admixed with polymorphous lymphocytes and cellular debris. microscopic findings: warthin tumors are composed of varying proportions of papillary- cystic structures lined by oncocytic epithelial cells and a lymphoid stroma with germinal centers. clinically, warthin tumor presents as a rounded or an ovoid nodular painless, slow-growing, fluctuant to firm at palpation. it can be unilateral, bilateral, or multicentric and is asymptomatic in 90% of cases. prognosis: warthin's tumor has a favorable prognosis and almost never recurs. malignant degeneration of warthin tumor is very rare. complications: local recurrence; the local recurrence rate is low; when recurrence does occur, it is probably due to multifocal tumors or inadequate excision. malignant transformation; malignant transformation in a warthin tumor is extremely rare. the most frequent histological types of malignant transformation in a warthin tumor are mucoepidermoid carcinoma, squamous cell carcinoma, undifferentiated carcinoma, oncocytic adenocarcinoma, and adenocarcinoma.

Eligibility criteria:
inclusion criteria: * all new cases presented with benign parotid cyst and diagnosed as warthin tumour in the parotid gland. exclusion criteria: * other parotid gland tumours e.g. solid tumours, malignant tumours and other suspicious tumours.
enhanced population-based core surveillance of meningococcal invasive infections at participating centers across canada

Conditions: Invasive Meningococcal Disease

Summary: active metropolitan area surveillance for hospital admissions related to invasive infection with neisseria meningitidis will be conducted at the 12 centers in the impact network in collaboration with public health officials, local infection specialists and infection control practitioners during the interval from january 1, 2016 to december 31, 2022.

the objectives are 3-fold, including: 1. description of affected children and adults and the nature and outcome of the infection episodes 2. incidence rate determination in defined populations, by age, serogroup and study year 3. detailed study of the organisms recovered from cases

Eligibility criteria:
inclusion criteria:neisseria meningitidis isolated or detected by pcr from a normally sterile body site or fluid, such as blood, csf, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy - exclusion criteria:patients diagnosed based only on 1. clinical signs, gram stain, or antigen test 2. meningococci isolated only from respiratory tract, including conjunctiva, sinuses, middle ear/mastoid, throat, peritonsillar abscess, cervical lymph node, tracheal aspirate, bronchial lavage etc -
continuously iterative perioperative holistic evaluation of risk and hypotension prediction index

Conditions: Surgery--Complications

Summary: the investigators would like to explore whether hypotension prediction index during and immediately after surgery can be used to improve the accuracy of scores that predict postoperative problems.

it is known that some patients have a prolonged and difficult recovery after major surgery, which impacts their long-term health and wellbeing. a major issue is that scores for predicting recovery are typically generated only once in the period before surgery, but subsequent events during and immediately after surgery can also alter the likelihood of a prolonged and difficult recovery. one such event appears to be low blood pressure (hypotension). hypotension prediction index can be calculated from routine blood pressure measurements, and is an indicator of blood pressure instability. the investigators propose that hypotension prediction index during and immediately after surgery may be used to improve their accuracy of scores that predict postoperative problems. to explore this, the investigators will collect information about the health and care needs, surgery and postoperative recovery of adult patients' requiring major surgery. this data will be taken from hospital information systems, a bedside monitor, test reports, a questionnaire and national databases. the investigators will then use statistical models to determine whether hypotension prediction index improves the accuracy of preoperative scores for predicting postoperative problems. ultimately, the investigators hope to create a tool for predicting how well a patient will recover based on the information available at any given point in time. healthcare professionals will be able to use this tool to identify and support the needs of patients who need extra help recovering from major surgery.

Eligibility criteria:
inclusion criteria: patients who: 1. are referred for cpet 2. are scheduled for elective surgery and expected to have \>24 hours postoperative hospital stay 3. will receive invasive arterial pressure monitoring as part of routine care 4. are aged 18 or over 5. have the capacity to give consent to participate exclusion criteria: patients who: 1. do not proceed to surgery following cpet referral 2. are aged less than 18 years 3. do not have capacity to consent 4. decline to consent

Keywords: perioperative medicine risk predictive analytics hypotension prediction index observational cohort
safety and performance of the endofast reliant scp in vaginal wall reinforcement

Conditions: Pelvic Organ Prolapse

Summary: a single arm, single site, retrospective cohort post marketing clinical follow up study evaluating the safety and performance of the endofast reliant scp for apical support.


Eligibility criteria:
inclusion criteria: 1. female subjects \>18 years old that underwent pelvic organ prolapse repair utilizing the endofast reliant scp exclusion criteria: 1. patients without follow-up
prophylactic treatment with atorvastatin for chronic migraine (chronicstatinmig)

Conditions: Chronic Migraine

Summary: the main objective of this study is to see whether the favorable preventative effect of atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. in addition it will be investigated whether 1) the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 2) estimating the cost of atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.


Eligibility criteria:
inclusion criteria: 1. age 18 to 64 years 2. signed informed consent 3. chronic migraine according to ichd-3 criteria (32) 4. at inclusion, patients should retrospectively have at least 15 headache days per month wheof at least 8 migraine days during the last 3 months. this frequency must be confirmed in the headache diary before randomisation to treatment (see below). 5. debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history 6. start of migraine before age 50 years. 7. no use of other migraine prophylactics during the study 8. for women of child-bearing potential (wocbp, see below) there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception (see below). after the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. if there are, according to the headache diary, fewer migraine days than 8 per month, the baseline period can be extended to 8 weeks. exclusion criteria: 1. medication overuse headache requiring detoxification from acute medication (triptans, opioids). exception could be made for those fulfilling a and b: a. have tried a withdrawal period of at least 2 months without impact on headache frequency b: use of opioids (of any type) ≤ 8 days /months. 2. pregnancy, planning to get pregnant, inability to use contraceptives (see inclusion criteria, point 8), and lactating 3. clinical information on or signs of cholestasis or decreased hepatic or renal function. 4. high degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator 5. hypersensitivity to statins or previous use of statins 6. history of angioneurotic oedema 7. use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study 8. current use of antiviral treatment agaist hepatitis c 9. significant psychiatric illness 10. alcohol or illicit drug dependence. 11. inability to understand study procedures and to comply with them for the entire length of the study 12. treatment for hypothyroidism 13. lactose intolerance

Keywords: migraine atorvastatin randomized controlled trial